SCHEMBL5458097

SCHEMBL5458097

Cc1nc(N)nc2c1C(=O)CC(c1ccccc1Oc1ccccn1)C2

nearest known ligand 0.57

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 12/20 0.57
HSP90AB1 P08238 10/20 0.57
TRAP1 Q12931 1/20 0.39
HPGD P15428 3/20 0.38
ALDH1A1 P00352 2/20 0.37
TSHR P16473 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
HSD17B10 Q99714 1/20 0.36
KDM4E B2RXH2 1/20 0.35
USP2 O75604 1/20 0.34
MAPT P10636 1/20 0.34
MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4618394 0.90 HSP90AA1 (0.60) HSP90AA1HSP90AB1TRAP1HPGDALDH1A1
SCHEMBL5472140 0.89 HSP90AA1 (0.54) HSP90AA1HSP90AB1TRAP1HPGDALDH1A1
SCHEMBL5468158 0.88 HSP90AA1 (0.60) HSP90AA1HSP90AB1TRAP1HPGDALDH1A1
SCHEMBL5457791 0.86 HSP90AA1 (0.55) HSP90AA1HSP90AB1TRAP1HPGDALDH1A1
SCHEMBL4620866 0.85 HSP90AA1 (0.65) HSP90AA1HSP90AB1TRAP1HPGDALDH1A1
SCHEMBL5471332 0.85 HSP90AA1 (0.62) HSP90AA1HSP90AB1TRAP1HPGDALDH1A1
SCHEMBL1779006 0.84 HSP90AA1 (0.66) HSP90AA1HSP90AB1TRAP1HPGDALDH1A1
SCHEMBL14582379 0.83 HSP90AA1 (0.60) HSP90AA1HSP90AB1TRAP1HPGDALDH1A1
SCHEMBL5465114 0.83 HSP90AA1 (0.60) HSP90AA1HSP90AB1TRAP1HPGDALDH1A1
SCHEMBL5463191 0.83 HSP90AA1 (0.62) HSP90AA1HSP90AB1TRAP1HPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070027150-A1 2-Amino-quinazolin-5-ones NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2007-02-01 US disclosed
US-20070027150-A1 2-Amino-quinazolin-5-ones NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2007-02-01 US disclosed
US-20070027150-A1 2-Amino-quinazolin-5-ones NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2007-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027150-A1 2-Amino-quinazolin-5-ones TK1, TK2, SLC1A5 HSP90AA1 3373/4885HSP90AB1 3036/4885TRAP1 2430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.